X-linked adrenoleukodystrophy: Pathogenesis and treatment

Current Neurology and Neuroscience Reports

Volumn 14, Issue 10, 2014, Pages 1-8

  Engelen, Marc ^a,b   Kemp, Stephan ^a,b   Poll The, Bwee Tien ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ABCD1; Hematopoietic cell transplantation; Peripheral neuropathy; Very long chain fatty acid myelopathy; Very long chain fatty acids; X linked adrenoleukodystrophy

Indexed keywords

ANTIOXIDANT; LORENZO OIL; PLACEBO; VERY LONG CHAIN FATTY ACID;

ABCD1 GENE; ADRENAL CORTEX INSUFFICIENCY; ADRENOLEUKODYSTROPHY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; HUMAN; LIPID STORAGE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SPINAL CORD DISEASE;

EID: 84919650999     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0486-0     Document Type: Review

References (77)

1. Heubner O. Über diffuse Hirnsclerose. Charite Ann. 1897;22:298–310.
2. Haberfield W, Spieler F. Zur diffusen Hirn-Ruckenmarksklerose im Kindesalter. Dt Z Nervheilk. 1910;40:436–63.
3. Siemerling E, Creutzfeldt HG. Bronzekrankheit und sklerosierende Enzephalomyelitis. Arch Psychiat Nervenkr. 1923;68:217–44.
4. Schilder PF. Zur Frage der Encephalitis periaxialis diffusa (sogenannten diffusen Sklerose). Z Gesamte Neurol Psychiatry. 1913;15:359–76.
5. Schilder PF. Die Encephalitis periaxialis diffusa (nebst Bemerkungen über die Apraxie des Lidschlusses). Arch Psychiatr Nervenkr. 1924;71:327–56.
6. Adams RD, Kubik CS. The morbid anatomy of the demyelinative disease. Am J Med. 1952;12(5):510–46.
7. Hoefnagel D, Brun A, Ingbar SH. Addison’s disease and diffuse cerebral sclerosis. J Neurol Neurosurg Psychiatry. 1967;30(1):56–60.
8. Hoefnagel D, Van Den Noort S, Ingbar SH. Diffuse cerebral sclerosis with endocrine abnormalities in young males. Brain. 1962;85:553–68.
9. Fanconi A, Prader A, Isler W, Luethy F, Siebenmann R. Addison’s disease with cerebral sclerosis in childhood. A hereditary syndrome transmitted through chromosome X? Helv Paediatr Acta. 1963;18:480–501.
10. Blaw ME, Osterberg K, Kozak P, Nelson E. Sudanophilic leukodystrophy and adrenal cortical atrophy. Arch Neurol. 1964;11:626–31.
11. Crome L, Zapella M. Schilder’s Disease (Sudanophilic leucodystrophy) in five male members of one family. J Neurol Neurosurg Psychiatry. 1963;26:431–8.
12. Blaw ME. Melanodermic type leukodystrophy (adreno-leukodystrophy). In: Vinken PJ, Bruyn CW, editors. Handbook of clinical neurology. New York: American Elsevier; 1970. p. 128–33.
13. Powers JM, Schaumburg HH. Adreno-leukodystrophy (sex-linked Schilder’s disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis. Am J Pathol. 1974;76(3):481–91.
14. Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem. 1976;26(4):851–60.
15. Penman RW. Addison’s disease in association with spastic paraplegia. Br Med J. 1960;1(5170):402.
16. Harris-Jones JN, Nixon PG. Familial Addison’s disease with spastic paraplegia. J Clin Endocrinol Metab. 1955;15(6):739–44. doi:10.1210/jcem-15-6-739.
17. Griffin JW, Goren E, Schaumburg H, Engel WK, Loriaux L. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. I. Clinical and endocrinologic aspects. Neurology. 1977;27(12):1107–13.
18. Schaumburg HH, Powers JM, Raine CS, Spencer PS, Griffin JW, Prineas JW, et al. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. II. General pathologic, neuropathologic, and biochemical aspects. Neurology. 1977;27(12):1114–9.
19. Budka H, Sluga E, Heiss WD. Spastic paraplegia associated with Addison’s disease: adult variant of adreno-leukodystrophy. J Neurol. 1976;213(3):237–50.
20. Migeon BR, Moser HW, Moser AB, Axelman J, Sillence D, Norum RA. Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A. 1981;78(8):5066–70.
21. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature. 1993;361(6414):726–30. doi:10.1038/361726a0.
22. Mosser J, Lutz Y, Stoeckel ME, Sarde CO, Kretz C, Douar AM, et al. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet. 1994;3(2):265–71.
23. Moser HW, Smith KD, Watkins PA, Powers J, Moser AB. X-linked adrenoleukodystrophy. In: Scriver CR, Sly WS, Childs B, Beaudet AL, Valle D, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw Hill; 2001. p. 3257–301.
24. van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol. 2001;49(2):186–94.
25. Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51. doi:10.1186/1750-1172-7-51. This review is especially useful to clinicians.
26. Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr. 2005;146(4):528–32. doi:10.1016/j.jpeds.2004.10.067.
27. Assies J, Gooren LJ, Van Geel B, Barth PG. Signs of testicular insufficiency in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy: a retrospective study. Int J Androl. 1997;20(5):315–21.
28. van Geel BM, Koelman JH, Barth PG, de Visser Ongerboer BW. Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. Neurology. 1996;46(1):112–8.
29. Horn MA, Nilsen KB, Jorum E, Mellgren SI, Tallaksen CM. Small nerve fiber involvement is frequent in X-linked adrenoleukodystrophy. Neurology. 2014;82(19):1678–83. doi:10.1212/WNL.0000000000000415.
30. Raymond GV, Seidman R, Monteith TS, Kolodny E, Sathe S, Mahmood A, et al. Head trauma can initiate the onset of adreno-leukodystrophy. J Neurol Sci. 2010;290(1–2):70–4. doi:10.1016/j.jns.2009.11.005.
31. Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 2012;1822(9):1465–74. doi:10.1016/j.bbadis.2012.03.012.
32. Van der Knaap MS, Valk J. X-linked adrenoleukodystrophy. In: Heilmann U, editor. Magnetic resonance of myelination and myelin disorders. Berlin: Springer; 2005. p. 176–90.
33. Engelen M, Barbier M, Dijkstra IM, Schur R, de Bie RM, Verhamme C, et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain. 2014;137(3):693–706. doi:10.1093/brain/awt361. This is a large prospective cohort study that systematically describes the phenotype of women with X-ALD.
34. El-Deiry SS, Naidu S, Blevins LS, Ladenson PW. Assessment of adrenal function in women heterozygous for adrenoleukodystrophy. J Clin Endocrinol Metab. 1997;82(3):856–60. doi:10.1210/jcem.82.3.3802.
35. Jangouk P, Zackowski KM, Naidu S, Raymond GV. Adrenoleukodystrophy in female heterozygotes: underrecognized and undertreated. Mol Genet Metab. 2012;105(2):180–5. doi:10.1016/j.ymgme.2011.11.001.
36. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson Jr EP. Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol. 1975;32(9):577–91.
37. Musolino PL, Rapalino O, Caruso P, Caviness VS, Eichler FS. Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy. Brain. 2012;135(9):2676–83. doi:10.1093/brain/aws206.
38. Phillips JP, Lockman LA, Shapiro EG, Blazar BR, Loes DJ, Moser HW, et al. CSF findings in adrenoleukodystrophy: correlation between measures of cytokines, IgG production, and disease severity. Pediatr Neurol. 1994;10(4):289–94.
39. Schaumburg HH, Richardson EP, Johnson PC, Cohen RB, Powers JM, Raine CS. Schilder’s disease. Sex-linked recessive transmission with specific adrenal changes. Arch Neurol. 1972;27(5):458–60.
40. Hoftberger R, Kunze M, Weinhofer I, Aboul-Enein F, Voigtlander T, Oezen I, et al. Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy. Neurobiol Dis. 2007;28(2):165–74. doi:10.1016/j.nbd.2007.07.007.
41. Moser HW, Moser AB, Frayer KK, Chen W, Schulman JD, O’Neill BP, et al. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology. 1981;31(10):1241–9.
42. Singh I, Moser HW, Moser AB, Kishimoto Y. Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex. Biochem Biophys Res Commun. 1981;102(4):1223–9.
43. Singh I, Moser AE, Moser HW, Kishimoto Y. Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res. 1984;18(3):286–90. doi:10.1203/00006450-198403000-00016.
44. Kemp S, Valianpour F, Mooyer PA, Kulik W, Wanders RJ. Method for measurement of peroxisomal very-long-chain fatty acid beta-oxidation in human skin fibroblasts using stable-isotope-labeled tetracosanoic acid. Clin Chem. 2004;50(10):1824–6. doi:10.1373/clinchem.2004.038539.
45. Kemp S, Mooyer PA, Bolhuis PA, van Geel BM, Mandel JL, Barth PG, et al. ALDP expression in fibroblasts of patients with X-linked adrenoleukodystrophy. J Inherit Metab Dis. 1996;19(5):667–74.
46. Wiesinger C, Kunze M, Regelsberger G, Forss-Petter S, Berger J. Impaired very long-chain acyl-CoA beta-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction. J Biol Chem. 2013;288(26):19269–79. doi:10.1074/jbc.M112.445445.
47. Tsuji S, Sano T, Ariga T, Miyatake T. Increased synthesis of hexacosanoic acid (C23:0) by cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). J Biochem. 1981;90(4):1233–6.
48. Kishimoto Y, Moser HW, Kawamura N, Platt M, Pallante SL, Fenselau C. Adrenoleukodystrophy: evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin. Biochem Biophys Res Commun. 1980;96(1):69–76.
49. Kemp S, Valianpour F, Denis S, Ofman R, Sanders RJ, Mooyer P, et al. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Mol Genet Metab. 2005;84(2):144–51. doi:10.1016/j.ymgme.2004.09.015.
50. Ofman R, Dijkstra IM, van Roermund CW, Burger N, Turkenburg M, van Cruchten A, et al. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol Med. 2010;2(3):90–7. doi:10.1002/emmm.201000061.
51. Engelen M, Schackmann MJ, Ofman R, Sanders RJ, Dijkstra IM, Houten SM, et al. Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation. J Inherit Metab Dis. 2012;35(6):1137–45. doi:10.1007/s10545-012-9471-4.
52. Engelen M, Tran L, Ofman R, Brennecke J, Moser AB, Dijkstra IM, et al. Bezafibrate for X-linked adrenoleukodystrophy. PLoS One. 2012;7(7):e41013. doi:10.1371/journal.pone.0041013.
53. Kemp S, Theodoulou FL, Wanders RJ. Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance. Br J Pharmacol. 2011;164(7):1753–66. doi:10.1111/j.1476-5381.2011.01435.x.
54. Powers JM, Schaumburg HH, Johnson AB, Raine CS. A correlative study of the adrenal cortex in adreno-leukodystrophy—evidence for a fatal intoxication with very long chain saturated fatty acids. Investig Cell Pathol. 1980;3(4):353–76.
55. Powers JM, Moser HW, Moser AB, Ma CK, Elias SB, Norum RA. Pathologic findings in adrenoleukodystrophy heterozygotes. Arch Pathol Lab Med. 1987;111(2):151–3.
56. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol. 2000;59(2):89–102.
57. Powers JM, DeCiero DP, Cox C, Richfield EK, Ito M, Moser AB, et al. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol. 2001;60(5):493–501.
58. Whitcomb RW, Linehan WM, Knazek RA. Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J Clin Investig. 1988;81(1):185–8. doi:10.1172/JCI113292.
59. Hein S, Schonfeld P, Kahlert S, Reiser G. Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum Mol Genet. 2008;17(12):1750–61. doi:10.1093/hmg/ddn066.
60. Galino J, Ruiz M, Fourcade S, Schluter A, Lopez-Erauskin J, Guilera C, et al. Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid Redox Signal. 2011;15(8):2095–107. doi:10.1089/ars.2010.3877.
61. Powers JM, Pei Z, Heinzer AK, Deering R, Moser AB, Moser HW, et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol. 2005;64(12):1067–79.
62. Lopez-Erauskin J, Galino J, Bianchi P, Fourcade S, Andreu AL, Ferrer I, et al. Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain. 2012;135(12):3584–98. doi:10.1093/brain/aws292.
63. Fourcade S, Lopez-Erauskin J, Galino J, Duval C, Naudi A, Jove M, et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet. 2008;17(12):1762–73. doi:10.1093/hmg/ddn085.
64. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet. 2002;11(5):499–505.
65. Eichler FS, Ren JQ, Cossoy M, Rietsch AM, Nagpal S, Moser AB, et al. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol. 2008;63(6):729–42. doi:10.1002/ana.21391.
66. Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW, et al. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A. 1997;94(17):9366–71.
67. Forss-Petter S, Werner H, Berger J, Lassmann H, Molzer B, Schwab MH, et al. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J Neurosci Res. 1997;50(5):829–43.
68. Kobayashi T, Shinnoh N, Kondo A, Yamada T. Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem Biophys Res Commun. 1997;232(3):631–6. doi:10.1006/bbrc.1997.6340.
69. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N, et al. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet. 2004;13(23):2997–3006. doi:10.1093/hmg/ddh323.
70. Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV, et al. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat. 2001;18(6):499–515. doi:10.1002/humu.1227.
71. Asheuer M, Bieche I, Laurendeau I, Moser A, Hainque B, Vidaud M, et al. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum Mol Genet. 2005;14(10):1293–303. doi:10.1093/hmg/ddi140.
72. Miller WP, Rothman SM, Nascene D, Kivisto T, DeFor TE, Ziegler RS, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood. 2011;118(7):1971–8. doi:10.1182/blood-2011-01-329235.
73. Loes DJ, Hite S, Moser H, Stillman AE, Shapiro E, Lockman L, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994;15(9):1761–6.
74. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326(5954):818–23. doi:10.1126/science.1171242.
75. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I, et al. A two-year trial of oleic and erucic acids (“Lorenzo’s oil”) as treatment for adrenomyeloneuropathy. N Engl J Med. 1993;329(11):745–52. doi:10.1056/NEJM199309093291101.
76. van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten Jr B, Wanders RJ, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo’s oil”. J Neurol Neurosurg Psychiatry. 1999;67(3):290–9.
77. Horn MA, Erichsen MM, Wolff AS, Mansson JE, Husebye ES, Tallaksen CM, et al. Screening for X-linked adrenoleukodystrophy among adult men with Addison’s disease. Clin Endocrinol. 2013;79(3):316–20. doi:10.1111/cen.12159.